Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...
Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...
After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...
Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...
Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...
NEW YORK, NY / ACCESSNEWSWIRE / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to "Neutral" from "Buy" given uncertainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback